CLASS II ONGOING Device recall · Reported 11 Nov 2026 · FDA Enforcement Report

Hemochron Jr., Whole Blood Microcoagulation System recalled

Accriva Diagnostics is recalling Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time, distributed nationwide in the US. The recall was initiated on 14 Sep 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: 10711234103012, Lot(Expiration): B6JCA005(02/28/2027), C6JCA008(03/31/2027), D6JCA011(04/30/2027), K5JCA041(10/31/2026), C6JCA007(03/31/2027)
Quantity recalled28710

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0317-2027
FDA event ID
99863
Recalling firm
Accriva Diagnostics, San Diego, CA
Classification
Class II
Status
Ongoing
Recall initiated
14 Sep 2026
FDA classified
30 Oct 2026
Reported
11 Nov 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

14 Sep 2026Recall initiated by company
30 Oct 2026Classified by FDA+46 days
11 Nov 2026Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Microcoagulation test used to evaluate low dose heparin anticoagulation has a mispositioned or absent clot activating reagent, which may result in out-of-range high error code, or erroneously high results, which may lead retest, or overestimation of patient's anticoagulation, leading to inadequate anticoagulant therapy, which could result in thrombosis.

Product as listed by the FDA

Hemochron Jr., Whole Blood Microcoagulation System, Activated Partial Thromboplastin Time (APTT) Test Cuvette, REF: J103

Where it was distributed

Worldwide - US Nationwide distribution in the states of MA, MO, AK, WV, NJ, TX, VA, IL, NY and the countries of China, Colombia.

Nationwide AlaskaIllinoisMassachusettsMissouriNew JerseyNew YorkTexasVirginiaWest Virginia

Questions about this recall

Why was it recalled?

Microcoagulation test used to evaluate low dose heparin anticoagulation has a mispositioned or absent clot activating reagent, which may result in out-of-range high error code, or erroneously high results, which may lead retest, or overestimation of patient's anticoagulation, leading to inadequate anticoagulant therapy, which could result in thrombosis.

Which lots are affected?

UDI-DI: 10711234103012, Lot(Expiration): B6JCA005(02/28/2027), C6JCA008(03/31/2027), D6JCA011(04/30/2027), K5JCA041(10/31/2026), C6JCA007(03/31/2027)

Where was it sold?

Worldwide - US Nationwide distribution in the states of MA, MO, AK, WV, NJ, TX, VA, IL, NY and the countries of China, Colombia.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 17 Nov 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Accriva Diagnostics

All 7

Other Other Medical Devices recalls

All 13,985